This week the FDA's Pharmacy Compounding Advisory Committee is meeting on July 23 and 24 to consider seven peptides, including BPC-157, for the 503A bulk drug substances list. A lot of the noise around it treats the meeting like a verdict. It is not one. Here is what actually happens.
A recommendation, not a rule
The committee's job is to vote and advise. That vote is not binding on the FDA. The agency can accept it, weigh it, or set it aside. Nothing about a substance's legal status changes the moment the panel raises its hands.
The FDA has said as much about its own briefing materials: those documents are proposals prepared for the committee, not final agency determinations, and no final call is made until the advisory input and all reviews are complete.
The four factors the panel weighs
For each peptide, the committee works through a four-factor test: the substance's physical and chemical characterization, its safety profile in compounding, the evidence of effectiveness for the intended use, and its history of use in compounding. It is a structured checklist, not a popularity contest, and the panel can reach different conclusions for different peptides on the same day.
What still has to happen after
Say the committee recommends against adding a peptide. That is a signal, not a switch. To actually change the list, the FDA has to decide whether to start formal rulemaking, publish a proposed rule, open a public comment period, and only then issue a final rule. That is a months-long process with more than one point where the public weighs in. We track each of those steps on our regulatory tracker.
Why this matters for the supply, not the molecule
Here is the part that gets lost in the countdown-clock coverage. Whatever the panel says this week, it does not touch the vials already shipping from anonymous overseas sellers. Those products are not verified for identity, potency, or sterility, and independent testing keeps turning up mislabeled and contaminated peptides. That grey market exists precisely because there is no legal, tested pharmacy pathway. A committee vote does not create one, and it does not make the unregulated supply any safer.
We say this openly because we disclose our interest: Peppies is an independent, for-profit venture that would benefit only from a future legal, tested market, and we make no claim that any peptide is safe or effective. None of these substances has been evaluated or approved by the FDA. Our point is narrower. If you are following this week's meeting, follow what it actually is: one advisory step in a long process, not the finish line.
Get notified when the FDA opens the comment window that carries legal weight.